Search Page
Save citations to file
Email citations
Email address has not been verified. Go to
My NCBI account settings
to confirm your email and then refresh this page.
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2018 | 1 |
| 2020 | 1 |
| 2025 | 0 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Page 1
Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial.
Blood. 2020 May 14;135(20):1739-1749. doi: 10.1182/blood.2020004823.
Blood. 2020.
PMID: 32160294
Free PMC article.
Clinical Trial.
Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials.
Jagasia M, Zeiser R, Arbushites M, Delaite P, Gadbaw B, Bubnoff NV.
Jagasia M, et al.
Immunotherapy. 2018 Apr;10(5):391-402. doi: 10.2217/imt-2017-0156. Epub 2018 Jan 10.
Immunotherapy. 2018.
PMID: 29316837
Free article.
Item in Clipboard
Cite
Cite
ARTICLE TYPE
ARTICLE LANGUAGE
AGE
Filters on the sidebar will be reset to the default list and any currently applied filters will be cleared.